



This cert

Certificate No : 2024/

Exporting Country : TÜRKİYE
Importing Country : MOLDOVA

1. Name and dosage for
PENEPIN JR. 0.15 mg
for injection (2 read)
- 1.1. Active ingredient(s):
Each PENEPIN JR
epinephrine as the a
For complete quality
see attached.⁴
- 1.2. Is this product licen:
in the exporting cou:
YES
- 1.3. Is this product acti
country? Yes/no/ur
If the answer to 1.2
omit section 2B.
If the answer to 1.2
with section 2B.⁶

2A.1. Number of product I
2014/832- 19 Nove

2A.2. Product-licence holc
VEM İlaç San. ve Tic.
Maslak Mahallesi AC
42 Maslak A Blok Sit
Sarıyer/İSTANBUL/
Factory address:
Çerkezköy Organize
Karaağaç Mahallesi
Kapaklı/TEKİRDAĞ,

2A.3. Status of product-lic
category as defined i
A

2A3.1. For categories b a
manufacturer producing the dosage form are :
(Key in appropriate category as defined in note 8)

2A.4. Is Summary Basis of Approval appended ?¹⁰ yes/no (key
in as appropriate): NO

2A.5. Is the attached, officially approved product information
complete and consonant with the licence?¹¹ yes/no/not
provided (key in as appropriate): Not provided.

2A.6. Applicant for certificate, if different from licence holder
(name and address) :¹²

This certificate is valid for 2 years from the date of issue unless submitted and approved information does not change.

Address: Söğütözü Mahallesi 2176. Sok. No:5 06520 Çankaya/ANKARA
P. + 90 312 218 30 00

APOSTILLE

(Convention de La Haye du 5 Octobre 1961)

1. Ülke/Country/Pays/Staat TÜRKİYE - LA TURQUIE

İşbu resmi belge/This public document/Le présent acte public/Dieses zeugnis wurde:

2. İbrahim Muaz YARADILMIŞ tarafından imzalanmıştır./Has been signed by/a été signé
par/durch ... unterschrieben

3. İmzalayanın sıfatı Daire Başkanı'dır./Acting in the capacity of/Agissant en qualité de/Titel des
Unterzeichneten

4. Türkiye İlaç ve Tıbbi Cihaz Kurumu 'nin mühür/damgasını taşımaktadır-bears the seal/stamp
of-/est revêtu du sceau/timbre de-trägt Siegel/Stempel von

TASDİK / CERTIFIED / ATTESTE / BEGLAUBIGUNG:

5. Çankaya Kaymakamlığı' da/at/à/in



6. 7.05.2024 günü/the/le/Am

7. Şef Ferah Diba ARSLAN tarafından/by/par/durch den/die

8. No : 222367 ile tasdik edilmiştir./No:/sous No:/unter Nr.

9. Mühür - Damga/Seal-stamp/Sceau-
timbre/Siegel-Stempel

10. İmza/Signature/Signature/Unterschrift:





REPUBLIC OF TÜRKİYE
MINISTRY OF HEALTH
TURKISH MEDICINES AND MEDICAL DEVICES AGENCY
Certificate of a Pharmaceutical Product¹

This certificate conforms to the format recommended by the World Health Organization
(General instructions and explanatory notes overleaf)

Certificate No : 2024/1403


Date: 30.04.2024

Exporting Country : TÜRKİYE
Importing Country : MOLDOVA

- | | |
|---|--|
| <p>1. Name and dosage form of product :
PENEPIN JR. 0.15 mg/0.3 ml I.M. auto injector with solution for injection (2 ready to use auto-injector/box)</p> <p>1.1. Active ingredient(s)² and amount(s) per unit dose :³ :
Each PENEPIN JR. auto injector contains 0.15 mg epinephrine as the active substance.
For complete qualitative composition including excipients, see attached.⁴</p> <p>1.2. Is this product licensed to be placed on the market for use in the exporting country?⁵ yes/no (key in as appropriate) : YES</p> <p>1.3. Is this product actually on the market in the exporting country? Yes/no/unknown (key in as appropriate): YES
If the answer to 1.2. is yes, continue with section 2A and omit section 2B.
If the answer to 1.2. is no, omit section 2A and continue with section 2B.⁶</p> <p>2A.1. Number of product licence⁷ and date of issue :
2014/832- 19 November 2014</p> <p>2A.2. Product-licence holder (name and address) :
VEM İlaç San. ve Tic. A.Ş.
Maslak Mahallesi AOS 55. Sokak
42 Maslak A Blok Sit. No: 2/134
Sarıyer/İSTANBUL/TÜRKİYE
Factory address:
Çerkezköy Organize Sanayi Bölgesi
Karaağaç Mahallesi Fatih Bulvarı No: 38
Kapaklı/TEKİRDAĞ/TÜRKİYE</p> <p>2A.3. Status of product-licence holder :⁸ a/b/c (key in appropriate category as defined in note 8)
A</p> <p>2A3.1. For categories b and c the name and address of the manufacturer producing the dosage form are :⁹
(Key in appropriate category as defined in note 8)
-----</p> <p>2A.4. Is Summary Basis of Approval appended ?¹⁰ yes/no (key in as appropriate): NO</p> <p>2A.5. Is the attached, officially approved product information complete and consonant with the licence?¹¹ yes/no/not provided (key in as appropriate): Not provided.</p> <p>2A.6. Applicant for certificate, if different from licence holder (name and address) :¹² -----</p> | <p>2B.1 Applicant for certificate (name and address) :
-----</p> <p>2B.2 Status of applicant : a/b/c (key in appropriate category as defined in note 8)
-----</p> <p>2B.2 For categories b and c the name and address of the manufacturer producing the dosage form are :⁹
-----</p> <p>2B.3 Why is marketing authorization lacking ?
Not required/not requested/under consideration/refused (key in as appropriate)
-----</p> <p>2B.4 Remarks :¹³
-----</p> <p>3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced ? yes/no/not applicable¹⁴ (key in as appropriate) : YES
If no or not applicable proceed to question 4.</p> <p>3.1. Periodicity of routine inspections (years) :
3 YEARS</p> <p>3.2. Has the manufacture of this type of dosage form been inspected ? yes/no (key in as appropriate) : YES</p> <p>3.3. Do the facilities and operations conform to GMP as recommended by the World Health Organization)¹⁵ yes/no/not applicable¹⁴ (key in as appropriate) : YES</p> <p>4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product ?¹⁶ yes/no (key in as appropriate): YES</p> <p>If no, explain : -----</p> |
|---|--|

This certificate is valid for 2 years from the date of issue unless submitted and approved information does not change.

Address: Söğütözü Mahallesi 2176. Sok. No:5 06520 Çankaya/ANKARA
P. + 90 312 218 30 00



General instructions

Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

Explanatory notes

1. This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.
2. Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.
3. The formula (complete composition) of the dosage form should be given on the certificate or be appended.
4. Details of quantitative composition are preferred but their provision is subject to the agreement of the product-licence holder.
5. When applicable, append details of any restriction applied to the sale, distribution or administration of the product that is specified in the product licence.
6. Sections 2A and 2B are mutually exclusive.
7. Indicate, when applicable, if the licence is provisional, or the product has not yet been approved.
8. Specify whether the person responsible for placing the product on the market:
 - (a) manufactures the dosage form;
 - (b) packages and/or labels a dosage form manufactured by an independent company; or
 - (c) is involved in none of the above.
9. This information can only be provided with the consent of the product-licence holder or, in the case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product licence. If the production site is changed, the licence has to be updated or it is no longer valid.
10. This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed.
11. This refers to product information approved by the competent national regulatory authority, such as Summary Product Characteristics (SPC)
12. In this circumstance, permission for issuing the certificate is required from the product-licence holder. This permission has to be provided to the authority by the applicant.
13. Please indicate the reason that the applicant has provided for not requesting registration.
 - (a) the product has been developed exclusively for the treatment of conditions — particularly tropical diseases — not endemic in the country of export;
 - (b) the product has been reformulated with a view to improving its stability under tropical conditions;
 - (c) the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import;
 - (d) the product has been reformulated to meet a different maximum dosage limit for an active ingredient;
 - (e) any other reason, please specify.
14. Not applicable means the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.
15. The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series No. 823, 1992, Annex 1. Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992, Annex 1).
16. This section is to be completed when the product-licence holder or applicant conforms to status (b) or (c) as described in note 8 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.

UNIT FORMULA

Product Name: **PENEPIN JR. 0.15 mg/0.3 ml I.M. Auto-Injector with Solution for Injection**

Pharmaceutical form: Auto-Injector with Solution for Injection

Dosage form: Each PENEPIN JR. auto injector contains 0.15 mg epinephrine.

Composition (1 Ready to use auto-injector):

Ingredients	Amount	Function	Reference
Active Substances			
Epinephrine*	0.16 mg*	Active substance	EP
Excipients			
Sodium chloride	1.8 mg	Isotonizer	EP
Sodium metabisulphite (E 223)	0.51 mg	Antioxidant	EP
*Hydrochloric acid	q.s. for pH = 3.4	pH adjuster	EP
Water for injection	q.s.p. 0.3 ml	Solvent	EP

*Includes 10% excess dose.

** %1 N HCl solution will be used for the pH adjustment.

Packaging: 2 ready to use auto-injector/box

Tufan ŞAHAN
Responsible Manager

VEM İLAÇ SANAYİ VE TİCARET A.Ş.
Maslak Mah. AOS 55. Sok. 42 Maslak A Blok
Sitt. No: 2734 Sarıyer/İSTANBUL
Tel: 0212 347 75 12-13 Fax: 0212 273 07 17
V.D. Maslak - VKN 9240498027